STMN2 and Parkinson disease: Moreover, reduced STMN2 expression was more recently reported in the brains of patients with Parkinson’s disease [44] and frontotemporal dementia [42] and in patients without TDP-43 pathology and in the absence of truncated STMN2, suggesting that STMN2 expression could be regulated by other mechanisms that are different from the TDP-43-related, cryptic exon pathway.